RestorFlora is a spore and yeast based probiotic formulated to enhance the effectiveness of MegaSporeBiotic. It helps reduce digestive symptoms associated with antibiotic therapy plus many more gastrointestinal concerns.
RestorFlora™ is a probiotic supplement that combines probiotic yeast and bacteria. This combination offers comprehensive digestive microbiome support with an advanced, dual-action approach to maintain a healthy intestinal environment. RestorFlora contains three well-studied and widely-used probiotic strains Saccharomyces boulardii, Bacillus subtilis HU58, and Bacillus clausii SC109. Used synergistically provides a profound benefit with a variety of gastrointestinal issues.
Form & Function
Due to its multiple yeast and spore strains, RestorFlora™ has the ability to effectively colonize the digestive tract in order to provide immune support among other supportive functions.
Research & Clinical Studies
Products containing only a single probiotic, such as Saccharomyces boulardii, has limitations with regards to gut restorative probiotic functions. RestorFlora contains three probiotic strains Saccharomyces boulardii, Bacillus subtilis HU58, and Bacillus clausii SC109 to enhance function and promote gut restoration. .
Saccharomyces boulardii is a non-pathogenic yeast probiotic that is well-studied and extensively used for its ability to support digestion and immune function. Additionally, Saccharomyces boulardii is capable of restoring barrier integrity, improving diarrhea and reducing inflammation (5). This yeast based probiotic changes the gut microbiome by decreasing species that are directly correlated with systemic levels of microbial translocation and inflammation (6).
Bacillus subtilis HU58
Bacillus subtilis HU58 is a high potency probiotic. A recent study has shown that supplementation probiotic Bacillus subtilis HU58 once a day for 7 days was well tolerated and safe compared to placebo (2, 3). Daily treatment with oral B. subtilis HU58 is also safe and well tolerated over a 4-week period in patients with hepatic encephalopathy. Additionally, the probiotic group showed a significantly reduced incidence of antibiotic associated diarrhea (AAH) (2) and significantly reduced blood ammonia level was observed in patients with a baseline level >60 µg/dL (3). A study on 18 apparently healthy subjects who took two capsules orally of Bacillus subtilis HU58 daily for 8 weeks showed immune modulation. This dosage was found to be safe and well tolerated without any side effects (4,7). Bacillus subtilis HU58™ has shown 100% survivability in the digestive tract, a 40% increase in short-chain fatty acid (SCFA) production, it helps maintain healthy digestion and is known to modulate healthy immune function (4,7).
Bacillus clausii SC109
Bacillus clausii SC109 is a spore forming bacterium. It is a probiotic that has been shown to have immunomodulatory effects and support healthy gastrointestinal function by being active against Gram-positive bacteria (Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile) (9). It has also been shown to be effective in the treatment of small intestinal bacterial overgrowth (SIBO) (10).
RestorFlora™ represents a significant advancement that overcomes these limitations of single probiotic use with the combination of Saccharomyces boulardii, Bacillus subtilis HU58™ and Bacillus clausii SC109.
Advantages of RestorFlora
RestorFlora supports a balanced intestinal flora due to its unique blend of spore based probiotics. These probiotics promote intestinal health, healthy bowel movement and improve digestion. RestorFlora also supports the body’s detoxification process and thereby supports healthy immune function. There’s shown to be an increase in short chain fatty acid production with supplementation of RestorFlora.
1-2 capsules per day with a meal, or as directed by your physician. Capsules may be opened to sprinkle contents on soft foods, water, juice, or other non-carbonated beverages for easy consumption.
Ages 5+: take 1 capsule daily with a meal or as directed by your healthcare practitioner.
Children under 5 years of age, please consult with your healthcare practitioner.
Currently, clinical research and application supports that there are no real contraindications for the use of RestorFlora.
- Dr Dilip Mehta, de Souza A, Jadhav SS, Devale M. “A Study of Probiotic Bacillus Subtilis HU58 for the Management of Antibiotic-Associated Diarrhoea in Adults”. The Indian Practitioner, Vol. 73, no. 4, Apr. 2020, pp. 22-28, http://articles.theindianpractitioner.com/index.php/tip/article/view/958.
- Yossef, Sayed et al. “An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy.” Evidence-based complementary and alternative medicine : eCAM vol. 2020 1463108. 30 Jun. 2020, doi:10.1155/2020/1463108
- Dound YA, Jadhav SS, Devale M, Tom Bayne, Kiran Krishnan, Mehta DS. “The Effect of Probiotic Bacillus Subtilis HU58 on Immune Function in Healthy Human”. The Indian Practitioner, Vol. 70, no. 9, June 2019, pp. 15-20, http://articles.theindianpractitioner.com/index.php/tip/article/view/293.
- Terciolo, Chloe et al. “Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption.” Clinical and experimental gastroenterology vol. 12 67-82. 11 Feb. 2019, doi:10.2147/CEG.S181590
- Villar-García, Judit et al. “Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.” PloS one vol. 12,4 e0173802. 7 Apr. 2017, doi:10.1371/journal.pone.0173802
- Markowiak-Kopeć, Paulina, and Katarzyna Śliżewska. “The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome.” Nutrients vol. 12,4 1107. 16 Apr. 2020, doi:10.3390/nu12041107
- Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006 Mar;40(3):235-43. doi: 10.1097/00004836-200603000-00015. PMID: 16633129.
- Urdaci, MC; Bressollier, P; Pinchuk, I (Jul 2004). “Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities”. Journal of Clinical Gastroenterology. 38 (6 Suppl): S86–90. doi:10.1097/01.mcg.0000128925.06662.69. PMID 15220667. S2CID 8725033.
- Gabrielli M, Lauritano EC, Scarpellini E, et al. (May 2009). “Bacillus clausii as a treatment of small intestinal bacterial overgrowth”. The American Journal of Gastroenterology. 104 (5): 1327–8. doi:10.1038/ajg.2009.91. PMID 19352343. S2CID 7920293.